395 related articles for article (PubMed ID: 31833259)
21. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
22. To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy.
Kumari A; Thakur M; Saha SC; Suri V; Prasad GRV; Patel FD; Radhika S
J Obstet Gynaecol; 2021 May; 41(4):616-620. PubMed ID: 32811236
[TBL] [Abstract][Full Text] [Related]
23. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
Bixel K; Vetter M; Davidson B; Berchuck A; Cohn D; Copeland L; Fowler JM; Havrilesky L; Lee PS; O'Malley DM; Salani R; Valea F; Alvarez Secord A; Backes F
Gynecol Oncol; 2020 Mar; 156(3):530-534. PubMed ID: 31937450
[TBL] [Abstract][Full Text] [Related]
24. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
[TBL] [Abstract][Full Text] [Related]
25. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
[TBL] [Abstract][Full Text] [Related]
26. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
Bregar A; Mojtahed A; Kilcoyne A; Kurra V; Melamed A; Growdon W; Alejandro Rauh-Hain J; Del Carmen M; Lee SI
Gynecol Oncol; 2019 Mar; 152(3):568-573. PubMed ID: 30642626
[TBL] [Abstract][Full Text] [Related]
27. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
[TBL] [Abstract][Full Text] [Related]
28. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study.
Wang D; Zhang G; Peng C; Shi Y; Shi X
J Ovarian Res; 2021 Mar; 14(1):49. PubMed ID: 33771198
[TBL] [Abstract][Full Text] [Related]
29. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
[TBL] [Abstract][Full Text] [Related]
30. Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer.
Merlo S; Besic N; Drmota E; Kovacevic N
Radiol Oncol; 2021 Aug; 55(3):341-346. PubMed ID: 33675192
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
Son JH; Lee JH; Jung JA; Kong TW; Paek J; Chang SJ; Ryu HS
Gynecol Oncol; 2018 Oct; 151(1):32-38. PubMed ID: 30122310
[TBL] [Abstract][Full Text] [Related]
32. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
[TBL] [Abstract][Full Text] [Related]
33. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
34. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.
Machida H; Tokunaga H; Matsuo K; Matsumura N; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Mikami M
Eur J Surg Oncol; 2020 May; 46(5):868-875. PubMed ID: 31818526
[TBL] [Abstract][Full Text] [Related]
35. Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer.
Nakamura K; Kitahara Y; Nishimura T; Yamashita S; Kigure K; Ito I; Kanuma T
World J Surg Oncol; 2020 Aug; 18(1):200. PubMed ID: 32791996
[TBL] [Abstract][Full Text] [Related]
36. Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis.
Chambers LM; Jia X; Rose PG; AlHilli M
Gynecol Oncol; 2021 Feb; 160(2):405-412. PubMed ID: 33221023
[TBL] [Abstract][Full Text] [Related]
37. Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850).
Marchetti C; Giannarelli D; Vizzielli G; Ferrandina G; Tortorella L; Fanfani F; Costantini B; Pasciuto T; Scambia G; Fagotti A
BJOG; 2023 Dec; 130(13):1579-1588. PubMed ID: 37334772
[TBL] [Abstract][Full Text] [Related]
38. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
39. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
Davidson BA; Broadwater G; Crim A; Boccacio R; Bixel K; Backes F; Previs RA; Salinaro J; Salani R; Moore K; Secord AA
Gynecol Oncol; 2019 Mar; 152(3):554-559. PubMed ID: 30558972
[TBL] [Abstract][Full Text] [Related]
40. Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study.
Liu X; Zhao Y; Jiao X; Yu Y; Li R; Zeng S; Chi J; Ma G; Huo Y; Li M; Peng Z; Liu J; Zhou Q; Zou D; Wang L; Li Q; Wang J; Yao S; Chen Y; Ma D; Hu T; Gao Q
J Ovarian Res; 2023 Jun; 16(1):121. PubMed ID: 37370087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
